MODULATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) RESISTANCE - A REVIEW

被引:185
作者
TIMMERBOSSCHA, H [1 ]
MULDER, NH [1 ]
DEVRIES, EGE [1 ]
机构
[1] UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV MED ONCOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS
关键词
D O I
10.1038/bjc.1992.249
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this review an inventory is made of agents used to circumvent cis-diamminedichloroplatinum(II) (CDDP) resistance in vitro and in vivo. Agents that affect CDDP accumulation and membrane related systems, cytoplasmic defense mechanisms, as well as DNA accessibility and repair are reviewed. In resistant cell lines that have decreased accumulation, this can be restored by hyperthermic treatment. With or without effects on accumulation compounds that affect cell signal transduction often increase CDDP cytotoxicity. Calcium channel blockers and calmodulin inhibitors do not seem to be uniformly good modulators of CDDP resistance. For transduction modulators as well as cellular calcium affecting agents mechanisms are mainly unclear or controversial. Glutathione appears, with the now available agents, to be the most promising target for modulation of cytoplasmic defense mechanisms. At the nuclear level the inhibition of DNA repair related enzymes as well as the use of modified nucleosides to interfere with repair is studied in various cell lines. Results with these agents suggest opportunities for clinically feasible cytotoxicity modulation. DNA accessibility could in vitro be affected, but seems to be an unreliable target for modulation. Whenever possible the resistance mechanism affected and the mode of action of the modulator are discussed. As an alternative for modulation another method of overcoming CDDP resistance namely the application of CDDP analogues is considered.
引用
收藏
页码:227 / 238
页数:12
相关论文
共 143 条
[11]   SERIAL DETERMINATIONS OF GLUTATHIONE LEVELS AND GLUTATHIONE-RELATED ENZYME-ACTIVITIES IN HUMAN-TUMOR CELLS-INVITRO [J].
BATIST, G ;
BEHRENS, BC ;
MAKUCH, R ;
HAMILTON, TC ;
KATKI, AG ;
LOUIE, KG ;
MYERS, CE ;
OZOLS, RF .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (13) :2257-2258
[12]  
BERD D, 1991, P AN M AM SOC CLIN, V10, P291
[13]  
BEREK J, 1989, OBSTET GYNECOL, V741, P663
[14]   ROLE OF ETOPOSIDE-BASED CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR RELAPSING GERM-CELL TUMORS [J].
BOSL, GJ ;
YAGODA, A ;
GOLBEY, RB ;
WHITMORE, W ;
HERR, H ;
SOGANI, P ;
MORSE, M ;
VOGELZANG, N ;
MACDONALD, G .
AMERICAN JOURNAL OF MEDICINE, 1985, 78 (03) :423-428
[15]  
CHAN TCK, 1988, CANCER RES, V48, P215
[16]  
CHANG BK, 1987, CANCER RES, V47, P2247
[17]   PHENOTYPIC REVERSION OF CISPLATIN RESISTANCE IN HUMAN-CELLS ACCOMPANIES REDUCED HOST-CELL REACTIVATION OF DAMAGED PLASMID [J].
CHAO, CCK ;
LEE, YL ;
LINCHAO, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 170 (02) :851-859
[18]  
CHAO CCK, 1991, CANCER RES, V51, P601
[19]   ENHANCEMENT OF CISPLATIN (DDP) ANTITUMOR-ACTIVITY BY 3-AMINOBENZAMIDE IN RAT OVARIAN-TUMORS SENSITIVE AND RESISTANT TO DDP INVIVO [J].
CHEN, G ;
ZELLER, WJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (01) :37-41
[20]  
CHEN G, 1988, CANCER CHEMOTH PHARM, V22, P303